Thursday, 23 May 2019BioPharmaChem Ireland (BPCI), the Ibec group that represents Biopharmaceutical and Chemical Manufacturing, celebrated 25 years in existence at its annual general meeting in Dublin, on Thursday, 23 May 2019.
Since its foundation in 1994, BPCI has overseen an extraordinary growth in the industry with Ireland’s exports from the sector increasing from €6 billion to €73 billion in 2018. In addition, employment increased during the period from 18,000 to over 30,000, with the result that Ireland is regarded internationally as being one of the industry’s most important manufacturing locations in the world.
Speaking at the annual meeting, BPCI Director, Matt Moran, said:
“The phenomenal growth of the sector in Ireland is no accident – it has been achieved by world class companies who continually focus on innovation and through delivering new and improved products to the market.
“Since we established the association, we have always tried to stay at the cutting edge including a campaign to encourage Government to focus on biotechnology in the mid-1990s. This has paid dividends and over the last decade alone, in excess of €1 billion euro per year has been invested by the industry in bio-manufacturing operations in Ireland. Looking forward, we need to focus on the next phase of development including the digitisation of manufacturing and advanced therapeutics.”
At the meeting, the BPCI elected a new Chair, Patricia Quane, Senior VP and General Manager, Astellas Ireland. Commenting, Ms Quane, said:
“I am delighted and feel privileged to accept the Chair of BPCI and l look forward to working with the membership to bring the industry to its next phase of innovation. We are proud of our international reputation with all of the top 10 global BioPharma companies operating in this country.”